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Abstract
Systemic lupus erythematosus (SLE) is characterised by the
production of autoantibodies against ubiquitous antigens,
especially nuclear components. Evidence makes it clear that the
development of these autoantibodies is an antigen-driven
process and that immune complexes involving DNA-containing
antigens play a key role in the disease process. In rodents,
DNase I is the major endonuclease present in saliva, urine and
plasma, where it catalyses the hydrolysis of DNA, and impaired
DNase function has been implicated in the pathogenesis of SLE.
In this study we have evaluated the effects of transgenic over-
expression of murine DNase I endonucleases in vivo in a mouse
model of lupus. We generated transgenic mice having T-cells
that express either wild-type DNase I (wt.DNase I) or a mutant
DNase I (ash.DNase I), engineered for three new properties –
resistance to inhibition by G-actin, resistance to inhibition by
physiological saline and hyperactivity compared to wild type. By
crossing these transgenic mice with a murine strain that
develops SLE we found that, compared to control non-
transgenic littermates or wt.DNase I transgenic mice, the
ash.DNase I mutant provided significant protection from the
development of anti-single-stranded DNA and anti-histone
antibodies, but not of renal disease. In summary, this is the first
study in vivo to directly test the effects of long-term increased
expression of DNase I on the development of SLE. Our results
are in line with previous reports on the possible clinical benefits
of recombinant DNase I treatment in SLE, and extend them
further to the use of engineered DNase I variants with increased
activity and resistance to physiological inhibitors.
Introduction
Systemic lupus erythematosus (SLE) is a disease character-
ized by the production of a variety of auto-antibodies against
ubiquitous intracellular and cell surface antigens. Detailed
analysis of these autoantibodies by many researchers has
revealed several key findings. First, nuclear antigens are prom-
inent with anti-double-stranded DNA (dsDNA) and anti-nucle-
osome antibodies extremely common in SLE patients
(reviewed in [1]). Second, immune complexes containing
these autoantibodies and nucleosomes are thought to medi-
ate pathology following their localization in tissues [2-4]. Third,
the anti-nuclear antibodies demonstrate all the hallmarks of an
antigen-driven, T-cell dependent mechanism [5]. The antibod-
ies are of high affinity, have undergone isotype switching and
show evidence of somatic mutation and epitope spreading [6].Page 1 of 11
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apoptotic cells provide the source of the nuclear antigens driv-
ing the development of autoimmunity. The autoantigens tar-
geted in SLE have been shown to cluster in and on the surface
blebs of apoptotic cells [7,8] and ablation in mice of a number
of genes whose products mediate the clearance of apoptotic
cells, such as C1q [9,10], secreted IgM [11,12], cMer [13,14]
and transglutaminase 2 [15,16] is associated with the devel-
opment of a lupus-like disease.
DNase I catalyses the hydrolysis of dsDNA, whether free or as
part of a nucleosome, and is the major endonuclease present
in saliva, urine and plasma in mice [17,18]. Impaired DNase I
function has been implicated in the pathogenesis of SLE for
many years since the initial observation that DNase activity is
low in the serum of patients with SLE [19] and in lupus-prone
NZB/NZW mice [20]. The reduced DNase I activity in SLE
patients also correlates with an increased serum concentra-
tion of globular actin (G-actin), a potent inhibitor of DNase
[19,21]. Mutations in Dnase1 have been identified in two Jap-
anese SLE patients, resulting in low DNase activity and severe
disease [22]. However, two subsequent studies failed to iden-
tify Dnase1 mutations among SLE patients of different ethnic
origin [23,24]. Of note, mice lacking DNase I (Dnase1-/-) have
been shown to develop a spontaneous lupus-like syndrome
[25]. These observations led to the speculation that DNase I
may regulate disease progression by degrading DNA released
from dying cells, thereby reducing the antigen load driving the
immune response, and by facilitating the hydrolysis of circulat-
ing and/or deposited DNA-antibody complexes [26].
There is already evidence that exogenous administration of
DNase may have some therapeutic activity in mice and
humans. On treating patients with SLE with bovine DNase I,
clinical responses were observed in six patients and three of
them showed a reduction in their levels of anti-DNA antibodies
[27] More recently, a phase 1b study of the use of recom-
binant human DNase I in patients with SLE demonstrated that
the treatment was safe. No change in serum markers of dis-
ease were observed, however, perhaps due to the fact that
catalytically active levels of the enzyme in the circulation were
achieved only for very brief periods [28]. In mice, the data have
been mixed, with Macanovic and colleagues [29] finding that
subcutaneous injection of recombinant DNase I led to signifi-
cant disease improvement in NZB/NZW mice, especially if the
DNase was administered during the most active stage of dis-
ease. However, in a second study, Verthelyi and colleagues
[30] reported that intraperitoneal injection of DNase I in young
NZB/NZW mice did not delay the onset, or reduce the sever-
ity, of glomerulonephritis, or prolong survival. One of the prob-
lems faced by both of these studies is that G-actin, a potent
inhibitor of DNase I activity, is present at high levels in both
SLE patients and NZB/NZW mice [19,21]. To address this
issue Lazarus and colleagues [31,32] have generated and
characterized a number of DNase I mutants, including ones
resistant to inhibition by G-actin. Mutations were also intro-
duced to increase the affinity of the DNase I for DNA, resulting
in two improved characteristics – increased specific activity
compared to the wild-type enzyme and elimination of the inhi-
bition by salt at physiological concentrations [31-34]. To test
the hypothesis that DNase I in vivo might protect from the
development of anti-nuclear antibodies and associated pathol-
ogy by reducing the circulating levels of antigenic nuclear
components, we have taken advantage of the mutant murine
DNase I constructs to generate transgenic mice over-express-
ing either wild-type (wt.DNase I) or the actin/salt-resistant
hyperactive mutant (ash.DNase I) protein. DNase transgenic
mice were inter-crossed with mice lacking serum amyloid P
component (Apcs-/-), previously shown to develop high titres
of anti-nuclear antibodies and glomerulonephritis [35,36], and
the phenotypes of the different transgenic mice in the pres-
ence or absence of serum amyloid P component were com-
pared. In this model, a mild protective effect of DNase I was
observed, with lower anti-single-stranded DNA (ssDNA) and
anti-histone antibody levels in transgenic mice compared to lit-
termate controls. In addition, in mice treated with lipopolysac-
charide (LPS), which induces a transient pulse of plasma
nucleosomes and DNA [37,38], a significant reduction in the
level of circulating DNA was observed in ash.DNase I trans-
genic mice. These data demonstrate that the therapeutic use
of a recombinant actin-resistant, salt-resistant and hyperactive
DNase I has potential to alter the development of autoimmu-
nity.
Materials and methods
Construction of DNase transgenic mice
The cDNA encoding murine wt.DNase I and a murine hyperac-
tive mutant resistant to inhibition by both salt and actin
(ash.DNase I) were made using methods previously described
[30-33]. The cDNA for the murine ash.DNase I contained
codons CGG:AAA at residues 13:205 and CGT at residue
114. This resulted in mutations E13R:T205K, which enhance
activity and impair inhibition by salt, and A114R to eliminate
inhibition by G-actin [30-33]. The cDNAs were inserted into
the human pVA vector (gift from Professor D Kioussis,
National Institute for Medical Research, London), which con-
tains the human CD2 control region [39,40]. The constructs
were excised from the vectors by digestion with Kpn I and Not
I, and purified using a QIAEX II gel extraction kit (Qiagen,
Crawley, UK) followed by Elutip purification (Schleicher and
Schuell, London, UK). The DNA was injected into fertilized
CBA × C57BL/6 F1 mouse eggs and these were transplanted
into foster females. Progeny were screened for transgene inte-
gration by slot blotting, using the human CD2 sequence as a
probe, and by PCR. Expression of transgenic DNase I was
measured in two ways: secretion of DNase from T cells puri-
fied from transgenic mice, as described below; and measuring
DNase activity in urine and serum by DNA-methyl green (DNA-
MG) assay, as described below. Several transgenic lines were
generated and the ones with the highest DNase I activity werePage 2 of 11
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I and ash.DNase I) were backcrossed to the C57BL/6 genetic
background for six generations before use.
Experimental cohorts
For studying spontaneous autoimmunity, the transgenic mice
were inter-crossed with Apcs-/-mice [35,36,41]. Cohorts of
more than 20 female mice per group (C57BL/6 (n = 45),
Apcs-/- (n = 44), wt.DNase I (n = 30), ash.DNase I (n = 25),
wt.DNase I.Apcs-/- (n = 21), ash.DNase I.Apcs-/- (n = 21))
were generated. Importantly, the control mice (C57BL/6 and
Apcs-/-) were littermates of the transgenic animals. Serum
samples were collected from all mice monthly from 3 months
of age, until sacrifice at 12 months, and stored at -80°C until
use. Animals were kept under specific pathogen-free condi-
tions. All animal care and procedures were conducted accord-
ing to institutional guidelines.
Serological analyses
Levels of IgG anti-nuclear antibodies were assessed by indi-
rect immunofluorescence using Hep-2 cells and a fluorescein-
conjugated IgG Fc-specific anti-mouse Ab (Sigma-Aldrich,
Dorset, UK). Serum samples were screened at a 1:80 dilution
in PBS supplemented with 2% BSA, 0.05% Tween 20,
0.02% NaN3 and the positive samples titrated to end point.
Figure 1
DNase I production in transgenic mice. (a) DNase secretion from lymph node cells was quantified by DNA-methyl green (DNA-MG) assay. Cells 
were placed in culture for 3 days either in (a) the absence or (b) presence of anti-CD3 antibodies. Supernatants were diluted in assay buffer 1:2 for 
unstimulated cells and 1:16 for stimulated cells. (c) Activity of the DNase I present in the supernatants purified as in (b). The activity was determined 
in the presence of the normal DNA-MG assay buffer, described in Materials and methods, or following the addition of 0.9% NaCl/ATP or NaCl/ATP/
Actin. The level of DNase I activity in the supernatants was adjusted to give similar levels in the normal DNA-MG assay buffer. (d) DNase I activity in 
the urine of actin-resistant, salt-resistant and hyperactive mutant of DNase I (ash.DNase I) transgenic mice compared to control C57BL/6 littermates. 
wt.DNase I, wild-type DNase I.Page 3 of 11
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were measured by ELISA as described previously [42]. Briefly,
plates were coated with ssDNA (10 µg/ml) or chromatin (0.5
mg/ml) for 3 hours at 37°C. Serum samples were screened at
1:100 and 1:300 dilution for anti-ssDNA and anti-chromatin
antibodies, respectively. Bound antibodies were detected with
AP-conjugated goat anti-mouse IgG (γ-chain specific; Sigma-
Aldrich), and the results were expressed in arbitrary ELISA
units (AEU) relative to a standard positive sample derived from
an MRL/Mp.lpr/lpr mice pool.
Total IgG antibodies to dsDNA were measured by ELISA as
previously described [43]. Briefly, plates were coated with 1
µg/mL streptavidin (Sigma-Aldrich), incubated overnight at
4°C and post-coated with PBS supplemented with 0.5%
BSA. φX174 double-stranded plasmid DNA (Promega, South-
hampton, UK) was biotinylated with Photoprobe biotin (Vector
Laboratories, Petersborough, UK), then added to the strepta-
vidin plate at 200 ng/ml and incubated overnight at 4°C.
Serum samples were assayed at 1:100 dilution, in triplicate
with one well per sample containing no dsDNA to allow deter-
mination of the non-specific binding to streptavidin. Bound
antibodies were detected and quantified as above.
Total IgG antibodies to histone were also measured by ELISA.
Plates were coated with calf thymus histone (5 µg/ml; Calbio-
chem, Nottingham, UK) overnight at 4°C. Serum samples were
screened at 1:100 dilution; bound antibodies were detected
and quantified as above.
Total IgM antibodies to ssDNA were measured by ELISA as
for IgG above, except serum samples were diluted 1:500 and
bound antibodies were detected with AP-conjugated goat
anti-mouse IgM (Sigma-Aldrich).
Renal histology and immunohistochemistry
Kidneys were fixed in Bouin's solution for at least 2 hours,
transferred into 70% ethanol, and processed into paraffin. The
sections were stained with periodic acid-Schiff reagent and
scored for glomerulonephritis. Glomerular hypercellularity was
ranked in a blinded fashion as follows: grade 0, normal; grade
I, hypercellularity involving greater than 50% of the glomerular
tuft in 25% to 50% of glomeruli; grade II, hypercellularity
involving greater than 50% of the glomerular tuft in 50% to
75% of glomeruli; grade III, hypercellularity involving greater
than 75% of the glomeruli or crescents in greater than 25% of
glomeruli; grade IV, severe proliferative glomerulonephritis in
greater than the 90% of glomeruli.
For quantitative immunofluorescence, fluorescein isothiocy-
anate (FITC)-conjugated goat antibodies against mouse total
IgM, IgG (Sigma-Aldrich) and C3 (ICN Pharmaceuticals, Bas-
ingstoke, UK) were used on snap-frozen sections. The staining
with FITC-conjugated antibodies was quantified as previously
described [44] and expressed as arbitrary fluorescence units.
The analysis was done blind and 50 glomeruli per section
were analysed.
Flow cytometry
Flow cytometry was performed using a three colour staining
on spleen cells and thymocytes and analysed with a FACSCal-
ibur™ (Becton-Dickinson, Mountain View, CA, USA). The fol-
lowing antibodies were used: anti-CD90.2 (53-2.1), anti-
B220 (RA3-6B2), anti-CD5 (53-7.3), anti-CD19 (1D3), anti-
CD25 (PC61), anti-CD69 (H1.2F3), anti-CD62L (MEL-14),
anti-CD44 (IM7), anti-CD4 (RM4-5) and anti-CD8 (53-6.7). All
antibodies were purchased from Pharmingen-Becton Dickin-
son (San Diego, CA, USA). Biotinylated antibodies were
detected using an allophycocyanin-conjugated streptavidin
antibody (Pharmingen-Becton Dickinson). Staining was per-
formed in the presence of saturating concentration of 24G2
monoclonal antibody (anti-FcγRII/III). Data were analysed
using WinMDI software (version 2.8, Scripps Institute, USA).
Table 1
Analysis of cell populations by flow cytometry
C57BL/6 (n = 3) ash.DNase I (n = 5) P
Spleen
CD4+ of all lymphocytes (%) 18.1 ± 1.4 18.0 ± 1.6 NS
B/T ratio 6.3 ± 0.2 5.7 ± 1.0 NS
CD4/CD8 ratio 1.6 ± 0.1 1.5 ± 0.2 NS
CD4+ expressing CD62L+ (%) 73.2 ± 2.6 72.8 ± 3.1 NS
Thymus
CD4/CD8+ lymphocytes (%) 81.6 ± 1.5 79.8 ± 2.4 NS
CD4+ CD8- lymphocytes (%) 3.6 ± 0.3 3.9 ± 0.4 NS
ash.DNase I = actin-resistant, salt-resistant and hyperactive mutant of DNase I; NS, not significant.Page 4 of 11
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Ninety-six-well microtitre plates (Nunc, Rochester, NY, USA)
were pre-coated overnight at 4°C with anti-CD3 (Pharmingen-
Becton Dickinson) diluted in PBS to 10, 3.3 and 1 µg/ml.
Before use, the plates were washed three times with PBS to
remove unbound antibody. Lymph nodes were removed from
transgenic mice and single cell suspensions prepared under
sterile conditions in RPMI containing 10% heat-inactivated
fetal calf serum, 100 µg/ml streptomycin, 100 units/ml penicil-
lin, 2 mM glutamine and 50 µM 2-mercaptoethanol. Finally,
cells were resuspended to 106, 3 × 105, and 105 cells/ml and
200 µl of each added to appropriate wells in uncoated or anti-
CD3 coated plates and incubated for 72 hours at 37°C.
DNase activity in the supernatants was measured by DNA-MG
assay, as set out below.
DNA-methyl green assay
DNase I activity in urine and supernatant samples was quanti-
fied using the colorimetric DNA-MG assay previously
described [45-47]. Mice were placed in metabolic cages for
24 hours to allow collection of urine. Calf-thymus DNA
(Sigma-Aldrich) was dissolved to 2 mg/ml in HEPES/EDTA
buffer (25 mM HEPES, 1 mM EDTA, pH 7.5) and methyl green
dye (Sigma-Aldrich) was dissolved to 0.4% in 20 mM Na-ace-
tate buffer, pH 4.2. To prepare the DNA-MG substrate, the dis-
solved dye (0.4%) was mixed with the calf-thymus DNA (2 mg/
ml) to make a final dye concentration of 0.02%. Multiple dilu-
tions of samples were made in MG-assay buffer (25 mM
HEPES, 4 mM CaCl2, 4 mM MgCl2, 0.1% BSA, 0.05% Tween
20, 0.05% NaN3, pH 7.5), mixed 1:1 with DNA-MG in a 96-
well microtitre plate (Nunc) and then incubated for 15 hours at
37°C. The absorbance was read in a plate reader using a 620
nm filter. DNase activity in the samples was calculated based
on a standard curve of recombinant bovine DNase I (Sigma-
Aldrich). In addition to the standard assay buffer, optimised to
generate maximal DNase activity, inhibitors of wild-type DNase
were added to the buffer. To measure the level of activity in the
presence of physiological salt, 0.9% NaCl was added to the
assay buffer and DNA-MG reagent. The DNA-MG reagent was
left overnight before use to allow for re-equilibration of the dye.
Samples were diluted in the buffer containing NaCl for at least
30 minutes prior to addition of the DNA substrate. To measure
inhibition of DNase I activity by G-actin, 0.4 mM ATP (Sigma-
Aldrich) was added the sample buffer, in addition to various
concentrations of G-actin (1 to 1000 µg/mL; Sigma-Aldrich).
Samples were diluted in the buffer containing G-actin/ATP for
at least 30 minutes prior to addition of the DNA substrate.
Lipopolysaccharide model
Female C57BL/6, wt.DNase I and ash.DNase I were injected
intraperitoneally with a single dose of 100 µg LPS from
Escherichia coli 0111:B4 (Sigma-Aldrich). Mice were bled
from the tail vein before, and 9 hours, 7 days and 14 days post-
injection of LPS.
Figure 2
Transient autoimmunity was induced in female C57BL/6 and actin-resistant, salt-resistant and hyperactive mut nt of DNase I (ash.DNase I) mice by in raperi o e l injection with a single dose of 100 µg lipopol-ys c haride (LPS; E. co i 0111:B4)
resistant, salt-resistant and hyperactive mutant of DNase I (ash.DNase 
I) mice by intraperitoneal injection with a single dose of 100 µg lipopol-
ysaccharide (LPS; E. coli 0111:B4). Serum and plasma samples were 
collected from mice before, and 9 hours, 7 days and 14 days post-LPS 
injection. (a) Plasma DNA concentration was determined by fluoromet-
ric assay with the dye PicoGreen, as described in the Materials and 
methods. Assays were performed in triplicate and values represent the 
mean results from each mouse. (b) Levels of serum IgM anti-ssDNA 
antibodies in mice before and 7 days and 14 days post-injection of 
LPS. Values are expressed in arbitrary ELISA units (AEU) related to a 
standard positive sample that was assigned a value of 100 AEU. (c) 
The level of IgM deposited in the glomeruli was quantified by immun-
ofluorescence and expressed as arbitrary fluorescence units (AFU). 
The data are representative of four separate experiments.Page 5 of 11
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20 mM), centrifuged to separate red blood cells and the
plasma stored at -80°C until use. The level of circulating DNA
was assessed by a PicoGreen (Molecular Probes, Eugene,
OR, USA) fluorimetric assay, as per the manufacturer's
instructions and as previously described [37,48]. Briefly, serial
plasma samples were made in TE buffer (10 mM Tris, 1 mM
EDTA, pH 8) and mixed at a 1:1 ratio with the PicoGreen rea-
gent, diluted 1:200 in TE buffer, in a 96-well microtitre plate
(Nunc). Fluorescence was measured using a Wallac Victor flu-
orescence plate reader (Perkin-Elmer, Groningen, The Nether-
lands) with an excitation wavelength at 485 nm and an
emission wavelength at 520 nm.
Statistics
The data are presented as mean ± standard error of the mean
(SEM), unless otherwise stated. The non-parametric Mann-
Whitney test was used to compare two groups and the
Kruskal-Wallis test with Dunn's multiple comparison test for
analysis of three groups, with differences being considered
significant for p values < 0.05. Statistics were calculated
using GraphPad Prism version 3.0 (GraphPad Software, San
Diego, CA, USA).
Results
Generation of DNase I transgenic lines
The cDNAs encoding murine wt.DNase I or the
E13R:A114R:T205K mutant DNase I (ash.DNase I), engi-
neered for resistance to inhibition by G-actin and physiological
salt as well as increased hydrolytic activity, were inserted into
the human CD2 Locus Control Region vector [39] that has
previously been shown to be effective in overcoming chromo-
somal position-dependent gene repression of heterologous
genes, allowing the production of the transgene in a predicta-
ble copy-number dependent manner [40]. The CD2 control
region directs expression of the transgene exclusively to the T
cell compartment. Mice containing the Dnase1 transgenes
were determined by Southern blot analysis, probing for the
human CD2 promoter elements encoded by the vector (data
not shown). For each construct, several lines of transgenic
mice were initially generated and those containing the highest
copy number were selected for subsequent backcrossing
onto the C57BL/6 strain for 6 generations. Semi-quantitative
slot blotting analysis showed that approximately 10 copies of
the transgene were present in wt.DNase I, whilst the
ash.DNase I mice contained eight copies (data not shown).
The DNase sequences were PCR amplified from the trans-
genic mice, and the products subjected to specific restriction
digests and sequenced (data not shown) to confirm the pres-
ence of the wt.DNase I or ash.DNase I construct.
To confirm the expression and secretion of DNase I from the T
cells in the transgenic mice, the lymph nodes were removed,
and single cell suspensions prepared and placed in culture in
vitro. In the absence of stimuli, the transgenic T cells only
secrete low levels of DNase I (Figure 1a); however, following
activation of the T cells by the pre-coating of the plate with anti-
CD3 antibodies (Figure 1b) or Concanavalin A (data not
shown), a large increase in the level of DNase I secreted into
the supernatant was observed compared to the level in the
supernatant from T cells of non-transgenic littermate mice. To
confirm the functional activity of the secreted DNase I, the
assay was also carried out in the presence of physiological salt
concentrations and G-actin. As expected, the DNase I
secreted from T cells purified from the wt.DNase I transgenic
mice was inhibited in the presence of 0.9% NaCl and G-actin,
Figure 3
Autoantibody profiles of the experimental cohorts at 12 months of age. 
(a) IgG anti-ssDNA titres in the serum of Apcs-/-, wt.DNase I. Apcs-/- 
and ash.DNase I. Apcs-/- mice. Values are expressed in arbitrary ELISA 
units (AEU) related to a standard positive sample that was assigned a 
value of 100 AEU. Each symbol represents one mouse. (b) Anti-histone 
titres in the same groups of mice as in (a), and statistics were per-
formed as described in the Materials and methods with significant dif-
ferences if p < 0.05. Error bars indicate standard error of the mean. NS, 
not significant.Page 6 of 11
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ash.DNase I mice was resistant to inhibition by NaCl and G-
actin (Figure 1c).
A significant increase in total DNase activity was also
observed in the 24 hour urine collection from transgenic mice
compared to their non-transgenic littermates (Figure 1d).
DNase activity was mainly measured from urine instead of
serum because the absence in urine of natural inhibitors of
DNase activity such as G-actin.
To test if the expression of DNase I from T cells in the trans-
genic mice had caused alterations in T-cell development or
introduced aberrations in the mature peripheral populations, a
comprehensive flow cytometry analysis was performed. Three-
colour analysis of the splenic and thymic cell populations did
not highlight any significant abnormalities (Table 1). Most
importantly, between the transgenic mice and littermate con-
trols, the percentage of CD4+CD8- cells within the thymus
(3.9 ± 0.4 and 3.6 ± 0.3, respectively), and the percentage of
naïve T cells within the periphery (72.8 ± 3.1 and 73.2 ± 2.6,
respectively) were identical.
LPS model of autoimmunity
Transient autoimmunity can be induced in mice by the adminis-
tration of a single high dose of LPS. This induces a pulse of
nucleosomes and chromatin in the plasma within the first 12
hours post-injection accompanied by an increase in circulating
anti-DNA antibody levels and immune-complexes deposited in
the kidneys [37,38,49,50]. To investigate if the increased
expression of DNase I could provide any protective effect in
this model, a single dose of 100 µg LPS (E. coli 0111:B4) was
injected intraperitoneally into DNase transgenic mice and their
non-transgenic littermates. This protocol was established fol-
lowing testing of a number of different forms of LPS, and a wide
range of doses, for their ability to induce a strong immunologi-
cal response without causing excessive toxicity to the mice.
Figure 2a shows that at 9 hours post-injection of LPS a large
increase in circulating DNA can be measured in the plasma of
non-transgenic mice, although significantly lower levels of cir-
culating DNA were observed in plasma from ash.DNase I trans-
genic mice. This observation clearly demonstrates that the level
of DNase activity is functionally higher in the ash.DNase I trans-
genic mice. No protective effect was observed in the wt.DNase
I transgenic mice compared to their littermate controls (data
not shown), most likely because the increased activity was neu-
tralised by the raised level of G-actin.
Circulating IgM anti-ssDNA antibodies were present in all
mice by day 7 post-injection of LPS and were still present at
day 14. No significant differences were observed in the either
the wt.DNase I or ash.DNase I transgenic mice compared to
non-transgenic mice (Figure 2b). No IgG anti-ssDNA antibod-
ies were detected in any mice. The kidneys were isolated from
all mice 14 days after the administration of LPS, and sections
stained for total IgM, IgG and C3. A significant increase in the
level of IgM deposited within the glomeruli was observed in all
mice when compared to non-infected mice. However, no sig-
nificant protective effect was observed in the ash.DNase I
transgenic mice (Figure 2c). The levels of glomerular C3 and
IgG deposition did not change following the LPS-injection.
Spontaneous autoimmunity
We have previously reported that Apcs-/- mice on the C57BL/
6 genetic background spontaneously develop a lupus-like dis-
ease [35,36]. Therefore, to study the role of DNase I in the
development of spontaneous autoimmunity, we inter-crossed
the DNase transgenic mice on the C57BL/6 genetic back-
ground with Apcs-/- (backcrossed onto C57BL/6 for 10 gen-
erations) mice and generated the following cohorts: wt.DNase
I, ash.DNase I, wt.DNase I.Apcs-/-, ash.DNase I.Apcs-/-,
C57BL/6 and Apcs-/-. Blood samples were collected from
mice at different time points and screened for the presence of
a variety of autoantibodies. Figure 3 and Table 2 show the final
results at 12 months of age when all the animals were sacri-
ficed. IgG anti-ssDNA (Figure 3a) and anti-histone (Figure 3b)
antibodies were significantly lower in the ash.DNase I.Apcs-/-
mice compared to both Apcs-/- and wt.DNase I.Apcs-/- ani-
mals. This protective effect of ash.DNase I on the generation
of anti-ssDNA autoantibodies was already present at six
Table 2
Autoantibody levels in serum of 12-month old mice
Antibody Apcs-/- (n = 44) wt.DNase I. Apcs-/- (n = 21) ash.DNase I. Apcs-/- (n = 21)
Anti-nucleara 1,280 (0–10,240) 2,560 (0–20,480) 320 (0–20,480)
Anti-dsDNAb 16.0 ± 8.9 9.2 ± 5.4 5.3 ± 3.5
Anti-chromatinb 8.8 ± 2.1 16.1 ± 5.1 10.6 ± 3.9
Anti-histoneb 56.7 ± 15.2 71.9 ± 17.0 18.6 ± 3.2 (p = 0.013)
Anti-ssDNAb 12.7 ± 2.7 10.1 ± 3.4 5.2 ± 2.1 (p = 0.008)
aValues are stated as medians (range in parentheses) based on end-point dilution. bAntibody levels are expressed as arbitrary ELISA units (AEU) 
relative to a standard positive sample that was assigned a value of 100 AEU. The data are presented as mean ± standard error of the mean. 
Statistics were performed comparing autoantibody levels from transgenic mice to the control Apcs-/- mice, as stated in Materials and methods. 
Unless stated, there were no significant differences (p > 0.05) between the groups. dsDNA, double-stranded DNA; ssDNA, single-stranded DNA.Page 7 of 11
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/- = 23.5 ± 7.2 AEU; p = 0.03). A trend towards lower IgG
anti-dsDNA antibody levels was also observed in the
ash.DNase I.Apcs-/- mice compared to control animals,
although this did not reach significance (Table 2). Anti-chro-
matin and anti-nuclear antibody titres were the same in all
three cohorts of mice (Table 2). It is noteworthy that no sero-
logical differences were observed between the wt.DNase
I.Apcs-/- and the Apcs-/- mice at any of the time points ana-
lysed. As expected, only very low levels of autoantibodies were
detected in any of the remaining cohorts (wt.DNase I,
ash.DNase I and C57BL/6; data not shown). The histological
assessment of the kidneys failed to reveal any significant ben-
eficial effect of the DNase transgenes on the development of
lupus-nephritis (Table 3).
Discussion
There is strong evidence for a role of DNase I in SLE with
DNase activity low in SLE patients and SLE-prone mice, and
Dnase1-/- mice developing a spontaneous lupus-like pheno-
type. Here we have shown that the transgenic expression of
mutant DNase I (ash.DNase I), conferring resistance to the
natural inhibitors of DNase I and having increased activity, can
provide some protective effect against the development of
autoantibodies in mice. However, the reduction in the autoan-
tibody level obtained in our experimental model was not suffi-
cient to prevent the mice from developing lupus nephritis.
Several different methods have been developed to measure
DNase I activity [51,52]. Measurement is difficult under physi-
ological conditions due to its low concentration in plasma, low
activity at physiological salt, pH dependence, and inhibition by
G-actin [19,20,46,47,51]. In our hands, the DNA-MG assay
proved to be consistent and reliable for screening the DNase
levels in mice. In healthy transgenic mice, modest increases in
the level of total DNase activity were obtained compared to
their littermate controls, even with high copy numbers of the
transgenes. The T cell stimulation assays demonstrate that fol-
lowing activation the transgenic T cells were able to secrete
large amounts of bioactive DNase; however, in the absence of
activation, the transgenic T cells only secreted low levels.
Therefore, the modest increases detected in biological fluids
(plasma and urine) probably reflected a general state of inacti-
vation of the peripheral T cells in healthy mice.
Previous studies have shown that DNA in the blood most likely
circulates in the form of nucleosomes that are released from
dead or dying cells [38], and is not freely soluble but in com-
plex with other blood proteins [53-55]. The poor clearance
and subsequent immunogenicity of these DNA complexes is
thought to be central to the pathogenesis of SLE. Thus, we felt
that it was important initially to demonstrate increased con-
sumption of these complexes in vivo in our transgenic mice.
Following the challenge of the transgenic mice with a high
dose of LPS, a significant reduction in the circulating levels of
potentially immunogenic DNA was obtained in the ash.DNase
I mice. This result clearly demonstrates that functionally the
transgenic DNase was active in vivo despite only modest
increases in total DNase activity detected in these mice. The
PicoGreen assay used to detect the circulating DNA is
extremely sensitive and has been shown to allow quantification
of soluble DNA as well as that bound within immune com-
plexes, and is not affected by the length of the DNA [48,56]. It
requires dsDNA to intercalate, however, and, therefore, any
circulating ssDNA could not be detected.
A number of groups have previously reported that the chal-
lenge of mice with a high dose of LPS leads to a transient
autoimmunity characterised by the development of a range of
autoantibodies of both the IgM and IgG isotypes, and subse-
quent glomerular disease [37,38,49,50]. In our hands, high lev-
els of IgM anti-ssDNA antibodies were induced in all mice
following the injection of LPS, although no subsequent devel-
opment of IgG anti-ssDNA antibodies was observed. In con-
trast to the profound protective effect of ash.DNase I
expression on the level of circulating DNA, no protection
against the development of the IgM anti-dsDNA antibodies was
provided. In view of the lack of IgG anti-ssDNA antibodies
observed in our experimental model, we believe that the
increase in IgM anti-ssDNA antibodies reflected a general
induction of B cell activation by LPS, and not an antigen driven
development of autoantibodies. In addition, we did not observe
any pathology in the kidneys of the mice, with the exception of
a general increase in deposited IgM. The sensitivity and
Table 3
Renal histological assessment in 12-month old mice
Histology gradea
0 I II III IV Total
Apcs-/- 8 (18) 18 (41) 12 (27) 5 (11) 1 (2) 44
wt.DNase I. Apcs-/- 4 (19) 8 (38) 5 (24) 3 (14) 1 (5) 21
ash.DNase I. Apcs-/- 4 (19) 7 (33) 5 (24) 5 (24) 0 (0) 21
aValues represent the number of mice (%) scored within that grade of glomerular hypercellularity. Grades 0 to IV are as described in Materials and 
methods. ash.DNase I, actin-resistant, salt-resistant and hyperactive mutant of DNase I; wt.DNase I, wild-type DNase I.Page 8 of 11
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the mouse strain and the type of LPS [49] used. Therefore, the
lower immunological response observed in our hands may
reflect differences in the experimental conditions applied.
Mice defective in a number of genes have provided important
insights into human SLE, presenting with similar disease phe-
notypes and leading to the identification of orthologous genes
or similar families of genes that drive disease in humans. We
and others have reported that deficiency in serum amyloid P
component leads to development of a spontaneous lupus-like
phenotype in mice [35,36]. Serum amyloid P component is
known to bind to chromatin [57-59] and apoptotic cells [60-
62]. Therefore, in its absence, it has been proposed that the
impaired removal of chromatin from the circulation is responsi-
ble for the development of the lupus-like disease observed in
Apcs-/- mice [35,36]. These observations made Apcs-/- mice
an ideal model to test whether increasing the concentration
and function of DNase I can protect mice from developing
autoimmunity. However, recently it has emerged that not all of
the autoimmune features observed in these mice is mediated
by deficiency of the Apcs gene [63]. Additional polygenic
genes in the region surrounding the knockout construct, a
locus on chromosome 1 known to be a hotspot for genes
implicated in SLE, also contribute to the development of dis-
ease. Despite these confounding factors, Apcs-/- mice on the
C57BL/6 genetic background spontaneously develop a
lupus-like disease and, therefore, still represent a suitable
model to test the role of DNase I in the disease process.
Importantly, to minimise any epistatic effect, non-transgenic lit-
termates were used as controls in this study.
In SLE, a huge range of autoantigens are targeted, although it
is complexes containing DNA and nucleosomes that are
thought central to pathogenesis. Tracking the development of
a range of autoantibodies from three months of age in the
cohorts revealed protection from the development of anti-
ssDNA and anti-histone in the ash.DNase I transgenic mice,
but only a non-significant decrease in the level of anti-dsDNA,
anti-nuclear or anti-chromatin antibodies. A possible explana-
tion for this is that, in these complexes, the DNA is present in
a different form, less susceptible to DNase digestion [48]. In
this context, it is of note that Macanovic and colleagues [29]
treated NZB/NZW mice with recombinant DNase I and
observed a reduction in the titre of anti-DNA but not anti-car-
diolipin antibodies. In addition, a recent report has demon-
strated that plasminogen co-operates with human and mouse
DNase I in the breakdown of chromatin within necrotic cells
[64]. The importance of this interaction in the overall function
of DNase I, especially with respect to removal of potentially
immunogenic chromatin complexes in vivo, remain to be con-
firmed, and it is possible that other related serine proteases
may also mediate this process. Thus, it is possible that the
level of additional accessory proteins present in our mice may
have limited the effectiveness of DNase I in vivo. Furthermore,
the significance of anti-DNA antibodies binding to DNase
leading to inhibition of its activity is still unclear [27,29,65] and
was not directly tested in this study. Thus it is possible that
some anti-dsDNA antibodies might have limited the DNase I
activity in vivo. Finally, the reason only mild protection from the
development of autoantibodies was observed in the
ash.DNase I transgenic mice may simply reflect the modest
expression levels obtained in these mice.
Mild glomerulonephritis was observed in all serum amyloid P
component-deficient cohorts, with no protection provided by
the over-expression of DNase I. As significantly lower levels of
anti-ssDNA antibodies were observed in the ash.DNase I
transgenic mice, one could conclude that in our experimental
model these autoantibodies were not critical in the early
stages of the renal disease. These findings are consistent with
data reported by Verthelyi and colleagues [30], who observed
lowered numbers of B cells secreting anti-DNA antibodies in
NZB/NZW mice treated with recombinant DNase I, but no
alteration to the renal function or overall clinical outcome. In
another study, however, significant improvement in the renal
pathology was reported, especially if the recombinant DNase
I was administered during the most active stage of disease
[29]. The discrepancy between the two studies could be due
to a number of factors, including the longevity of the injected
protein and the level of free G-actin in the circulation at sites
of inflammation inhibiting the DNase I activity. Our data
obtained by a transgenic expression of the mutant protein
(ash.DNase I) in T cells appear to favour the hypothesis that
DNase I cannot alter the initial stages of glomerular disease.
However, as only mild renal disease developed in the mice
used in our study, we were unable to shed any light on the role
of DNase I in the more advanced stages of lupus nephritis. It
has been proposed that decreased levels of DNase activity
may be responsible for the persistence of immune complexes
in the basement membrane, allowing disease progression
[29]. In addition, previous studies have demonstrated that
engineered variants of human DNase I can dissociate DNA
antibody immune complexes and proposed that this could pro-
vide protection against some of the pathological effects of
these complexes in the glomeruli [31,32]. Therefore, studies in
mice that develop a more severe immune complex mediated
glomerulonephritis will be required to test these hypotheses.
In addition to the mouse models of SLE, two studies have
been carried out in patients to test the therapeutic effect of
recombinant human DNase I [27,28]. Repeated injections
were well tolerated but the protein had a short half-life within
the periphery and gave no clinical remission. The results pre-
sented here suggest that actin/salt-resistant and hyperactive
variants of human DNase I, previously shown to have improved
activity in vitro and in the digestion of mucus from cystic fibro-
sis patients [31], provide greater protection than the wild-type
DNase I and could be considered as a potential therapeutic
approach. In addition, the clinical manifestations are morePage 9 of 11
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whereas in mice glomerulonephritis is the main disease phe-
notype. Therefore, extended human trials of human DNase I
will provide insights into its potential protective properties in a
wider range of tissues.
Conclusion
This is the first study to directly test the in vivo effect of DNase
I on the development of lupus-like disease through transgenic
protein expression. Our findings indicate that the presence of
a mutant DNase (ash.DNase I), resistant to inhibition by serum
G-actin, resistant to inhibition by physiological saline and
hyperactive compared to the wild-type protein, can provide
protection from the development of anti-DNA antibodies, but
not renal disease. These results are in line with previous
reports on the possible clinical benefits of recombinant DNase
I treatment in SLE, and extend them further to the use of engi-
neered DNase I variants with increased activity and resistance
to physiological inhibitors.
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